Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2021-09-17

FDA Approved: SEGLUROMET — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

FDA approved a supplemental application for Segluromet (ertugliflozin and metformin HCl) submitted by Merck to update the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SEGLUROMET (ertugliflozin and metformin hydrochloride)

Snippet

SUPPL AP for SEGLUROMET (ERTUGLIFLOZIN AND METFORMIN HYDROCHLORIDE)